{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-25-000030","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.566088+00:00","generated_at":"2026-05-17T18:43:39.290604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead Q2: revenue $7.1B, Biktarvy +9%, product sales ex-Veklury +4%; FY guidance raised","bullets":["Revenue $7.1B (+2% YoY), product sales ex-Veklury $6.9B (+4%); Biktarvy $3.5B (+9%).","GAAP diluted EPS $1.56 vs $1.29 YoY; non-GAAP diluted EPS $2.01, flat YoY.","FY2025 guidance raised: product sales $28.3-28.7B, diluted EPS $5.85-6.15, non-GAAP EPS $7.95-8.25.","HIV sales +7% to $5.1B; Trodelvy +14% to $364M; Cell therapy -7% to $485M.","FDA approved Yeztugo as first twice-yearly HIV prevention; MYR impairment $190M."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-25-000030","json":"https://secwatch.observer/filing/0000882095-25-000030.json","markdown":"https://secwatch.observer/filing/0000882095-25-000030.md","text":"https://secwatch.observer/filing/0000882095-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/0000882095-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/gild-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:43:39.290604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}